We provide you with 20 years of free, institutional-grade data for CKPT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CKPT. Explore the full financial landscape of CKPT stock.
| Reported Date | CIK | Ticker | Type |
|---|
Checkpoint Therapeutics, Inc(NASDAQ:CKPT) 
Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal ...
Website: http://www.checkpointtx.com
Founded: 2014
Full Time Employees: 8
CEO: James Oliviero
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about CKPT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.